Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 24, 2020, discloses two material definitive agreements entered into by Cryoport, Inc. (the "Company"). The filings detail the acquisition of the MVE cryobiological storage business from Chart Industries, Inc. and a concurrent private placement financing with an affiliate of The Blackstone Group Inc. to fund the transaction.
Key Financial Metrics and Transaction Terms
- Acquisition Price: $320 million in cash for the MVE cryobiological storage business, subject to customary working capital adjustments.
- Financing Amount: $275 million aggregate purchase price raised via private placement.
- Financing Structure:
- $250 million for 250,000 shares of 4.0% Series C Convertible Preferred Stock ($1,000 per share).
- $25 million for 675,536 shares of Common Stock.
- Preferred Stock Terms:
- Dividend: 4.0% per annum, paid-in-kind, accruing daily and paid quarterly.
- Conversion Price: $38.6152 per share of Common Stock.
- Liquidation Preference: Senior to Common Stock; entitled to the greater of the purchase price plus accrued dividends or the as-converted value.
- Redemption: Company may redeem up to 50,000 shares within 6 months at 125% of purchase price; all shares redeemable at 105% after 5 years and 100% after 6 years.
- Debt Covenants: While 75% of Series C Preferred Stock is outstanding, the Company cannot incur indebtedness unless the pro forma debt-to-LTM EBITDA ratio is less than 5-to-1.
Material Changes and Strategic Impact
The Company has entered into a definitive agreement to acquire Chart Industries' MVE cryobiological storage business, a strategic move to expand its capabilities in the cryobiological logistics sector. This represents a significant capital deployment and a shift in the Company's capital structure through the issuance of senior preferred equity. The transaction is expected to close in 2020, subject to regulatory approvals and customary closing conditions.
Guidance, Outlook, and Risks
Outlook: Management expects the MVE Acquisition and Private Placement to close substantially simultaneously in 2020. The Company intends to use net proceeds from the financing to fund the purchase price, transaction fees, and working capital.
Risks and Contingencies:
- Closing Conditions: The transaction is subject to the expiration of the Hart-Scott-Rodino waiting period, absence of governmental injunctions, and no material adverse effect on the MVE business.
- Termination: Either party may terminate the agreement if the transaction is not completed by December 31, 2020, subject to automatic extensions and breach limitations.
- Forward-Looking Statements: Actual results may differ due to regulatory delays, unexpected costs, market acceptance risks, and general economic conditions.
Investor Verification Checklist
- Verify the final closing date and confirmation of regulatory approvals (Hart-Scott-Rodino).
- Review the full text of the Purchase Agreement (Exhibit 2.1) for specific working capital adjustment mechanisms.
- Monitor the Company's cash balance to ensure sufficient liquidity to cover the $45 million gap between the $320 million purchase price and the $275 million financing proceeds.
- Assess the impact of the 4.0% paid-in-kind dividend on future cash flow and earnings per share.
- Confirm the appointment of the Blackstone-affiliated director to the Board of Directors.